Green Cross stock: IBK Securities keeps target at KRW 190,000

Published on 10/23/2026 at 05:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

IBK Securities kept its KRW 190,000 target on October 21, 2026. A KRW 524.4 billion third-quarter revenue forecast frames Green Cross stock.

Analyst view and operating data

IBK Securities kept a KRW 190,000 target for October 21, 2026.
Daol projected KRW 40.9 billion in third-quarter operating profit, up 40.00 percent year over year.
Fiscal-year 2025 revenue reached KRW 1.9913 trillion, up 18.54 percent.

Green Cross, KR7006280002, Illustration mit AI erstellt.

Green Cross (ISIN KR7006280002) is tied to an IBK Securities target of KRW 190,000 dated October 21, 2026, according to CHOSUNBIZ. The analyst house kept its Buy rating while forecasting weaker third-quarter revenue but stronger operating profit. For investors, the central question is whether high-margin products can offset softer COVID-19 treatment sales.

Three events shape the earnings view

The recent sequence points toward a more selective growth story. On October 2, GC Green Cross said its proprietary messenger RNA lipid nanoparticle platform achieved more than 50.00 percent higher protein translation efficiency than benchmarks, as Asiae reported. On October 13, GC Biopharma announced analyses covering six lots of ALYGLO and three lots each of four other intravenous immunoglobulin products through Business Wire. The latest event was the October 21 IBK Securities forecast.

What supports the profit forecast?

Seoul Economic Daily reported on October 20 that Daol Investment and Securities projected third-quarter revenue of KRW 522.3 billion, down 14.30 percent year over year, and operating profit of KRW 40.9 billion, up 40.00 percent. The operating profit estimate stood 19.10 percent above consensus of KRW 34.4 billion, while revenue was 12.20 percent below consensus of KRW 594.8 billion.

The product mix explains the split. Daol forecast domestic vaccine revenue up 46.00 percent and ALYGLO sales up 62.00 percent year over year, while Paxlovid demand weighed on the revenue comparison. IBK Securities separately estimated revenue of KRW 524.4 billion, down 14.00 percent, and operating profit of KRW 40.8 billion, up 39.80 percent.

Operating base remains material

Green Cross entered this forecast cycle after fiscal-year 2025 revenue of KRW 1.9913 trillion, an 18.54 percent increase, according to El Fondo. The same profile identifies the company as a South Korean pharmaceutical group focused on blood-related therapies, medicines and immunizations. That base makes the current debate less about broad sales expansion and more about product mix, subsidiary costs and the durability of ALYGLO demand.

Listing and company profile

GC Biopharma is the current name of Green Cross Corporation and is headquartered in Yongin, South Korea. Its portfolio includes plasma-derived therapies and vaccines, giving the earnings discussion a direct link to both seasonal vaccine shipments and the United States launch of ALYGLO.